This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the biggest challenges for allogeneic T cell programs and what advantages these may have over autologous T cells

Ticker(s): IBB

Who's the expert?

Obtained his PhD in Hungary at University of Debrecen, where he became fascinated by biophysical techniques that he learned to use to study molecular interactions in living cells. He was further trained in the Babraham Institute In Cambridge (UK) and later at the ErasmusMC in Rotterdam (NL) where he as postdoctoral fellow has studied the molecular needs of genetic engineering of T cells for the immunotherapy of cancer. He continued his career at the UMCU in Utrecht, where he was appointed in 2014 as staff member of Section Applied within the Laboratory of Translational Immunology. As Associate Professor, he is currently focusing on the molecular mechanisms of innate T cell and tumour cell interactions and their translational options for future therapies. Research interest: immunotherapy of cancer, tumour recognition of innate immune cells, immune receptors, genetic engineering.

Interview Goal
Discussing next generation cell therapy in the oncology space with a focus on gamma delta (γδ) T Cells and their therapeutic indications

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.